Thomas M. Jr. File

Thomas M. Jr. File's AcademicInfluence.com Rankings

Thomas M. Jr. File

Philosophy

#7202

World Rank

#10380

Historical Rank

Logic

#4270

World Rank

#5540

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Thomas M. Jr. File's Degrees

Doctorate Medicine University of California, San Francisco
Masters Public Health University of California, Berkeley

Why Is Thomas M. Jr. File Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Thomas M. Jr. File's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (2007) (5734)
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. (2001) (2190)
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults (2000) (2147)
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. (2016) (2131)
Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011. (2016) (1192)
Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults (2003) (1016)
Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. (1997) (956)
Community-Acquired Pneumonia in Adults: Guidelines for Management (1998) (854)
Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. (2009) (666)
Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial (1995) (658)
Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. (2002) (642)
IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. (2012) (511)
Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. (1996) (423)
Burden of Community-Acquired Pneumonia in North American Adults (2010) (412)
Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. (2016) (385)
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia (1997) (366)
Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. (2002) (296)
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. (2018) (287)
Community-acquired pneumonia (2003) (258)
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. (2019) (248)
A worldwide perspective of atypical pathogens in community-acquired pneumonia. (2007) (229)
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections (2019) (222)
Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. (2012) (212)
Reevaluation of the definition of Legionnaires' disease: use of the urinary antigen assay. Community Based Pneumonia Incidence Study Group. (1995) (196)
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. (2011) (189)
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. (2010) (188)
Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? (1996) (184)
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. (2011) (168)
OUTBREAK OF CENTRAL-NERVOUS-SYSTEM TOXOPLASMOSIS IN WESTERN EUROPE AND NORTH AMERICA (1983) (159)
Risk factors for domestic acquisition of legionnaires disease. Ohio legionnaires Disease Group. (1996) (151)
Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. (2000) (149)
Risk factors for domestic acquisition of legionnaires disease. Ohio legionnaires Disease Group (1996) (148)
Accuracy of ICD-9-CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies. (1999) (142)
Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. (1998) (133)
Streptococcus pneumoniae and community-acquired pneumonia: A cause for concern (2004) (127)
The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. (1998) (124)
A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. (2012) (115)
A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria. (2005) (111)
Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. (1999) (101)
The Radiologic Manifestations of Legionnaire's Disease (2000) (101)
Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. (2004) (98)
Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. (2003) (97)
Summary of ceftaroline fosamil clinical trial studies and clinical safety. (2012) (96)
Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. (2002) (95)
The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. (2008) (94)
The epidemiology of respiratory tract infections. (2000) (91)
Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. (2013) (87)
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial (2019) (85)
Overview of resistance in the 1990s. (1999) (85)
Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. (1996) (79)
Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. (2006) (75)
Antimicrobial stewardship: importance for patient and public health. (2014) (73)
Group A streptococcal necrotizing fasciitis. Diagnosing and treating the "flesh-eating bacteria syndrome". (1998) (72)
High-pressure liquid chromatographic method for analysis of cephalosporins (1984) (71)
SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. (2016) (68)
Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. (2007) (66)
Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group (1996) (65)
Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. (2004) (60)
Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. (2004) (58)
The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. (2000) (57)
Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Levofloxacin versus Ceftriaxone Sodium and Erythromycin Followed by Clarithromycin and Amoxicillin- Clavulanate in the Treatment of Serious Community-Acquired Pneumonia in Adults (2004) (57)
An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy (2012) (56)
Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. (2002) (55)
“Management of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies” (2020) (51)
Necrotic skin lesions associated with disseminated candidiasis. (1979) (51)
Eight Habits of Highly Effective Antimicrobial Stewardship Programs to Meet the Joint Commission Standards for Hospitals (2017) (50)
An Outbreak of Pseudomonas aeruginosa Ventilator-Associated Respiratory Infections Due to Contaminated Food Coloring Dye - Further Evidence of the Significance of Gastric Colonization Preceding Nosocomial Pneumonia (1995) (49)
Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines. (2010) (48)
What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? (2003) (47)
Radiographic appearance of Chlamydia pneumoniae (TWAR strain) respiratory infections. CBPIS Study Group. Community-based Pneumonia Incidence Study. (1994) (47)
Guidance for the Knowledge and Skills Required for Antimicrobial Stewardship Leaders (2014) (47)
Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. (2019) (46)
Short-course treatment of community-acquired pneumonia. (2003) (45)
Antimicrobial therapy of community-acquired pneumonia (2004) (45)
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. (2001) (44)
Strategies for improving antimicrobial use and the role of antimicrobial stewardship programs. (2011) (44)
Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. (2002) (43)
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1 (2017) (42)
Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. (2005) (41)
HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study. (2005) (41)
Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremia. (2007) (40)
Gemifloxacin versus Amoxicillin/Clavulanate in the Treatment of Acute Exacerbations of Chronic Bronchitis (2000) (40)
Rational use of antibiotics to treat respiratory tract infections. (2002) (39)
Legionnaires disease with bacteremic coinfection. (2002) (39)
Double-Blind, Randomized Study of the Efficacy and Safety of Oral Pharmacokinetically Enhanced Amoxicillin-Clavulanate (2,000/125 Milligrams) versus Those of Amoxicillin-Clavulanate (875/125 Milligrams), Both Given Twice Daily for 7 Days, in Treatment of Bacterial Community-Acquired Pneumonia in Adu (2004) (37)
Bacterial Pneumonia in Older Adults. (2016) (37)
Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. (1999) (37)
Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. (1988) (37)
Amdinocillin plus cefoxitin versus cefoxitin alone in therapy of mixed soft tissue infections (including diabetic foot infections). (1983) (35)
Prevalence and Antibacterial Susceptibility of mef(A)-Positive Macrolide-Resistant Streptococcus pneumoniae over 4 Years (2000 to 2004) of the PROTEKT US Study (2006) (34)
The science of selecting antimicrobials for community-acquired pneumonia (CAP). (2009) (34)
Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. (2001) (34)
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study) (2018) (33)
Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program Guidelines. (2016) (32)
Impact of an antimicrobial stewardship program on patients with acute bacterial skin and skin structure infections. (2014) (29)
Timentin versus piperacillin or moxalactam in the therapy of acute bacterial infections (1984) (29)
Emergence of methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of late-onset nosocomial pneumonia in intensive care patients in the USA. (2013) (28)
Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration (1992) (28)
Predisposing factors and antibiotic use in nosocomial infections caused by Xanthomonas maltophilia. (1992) (27)
Does empiric therapy for atypical pathogens improve outcomes for patients with CAP? (2013) (26)
Effect of Introducing Procalcitonin on Antimicrobial Therapy Duration in Patients With Sepsis and/or Pneumonia in the Intensive Care Unit (2014) (26)
Overview of Resistance in the 1990 s (25)
How long should we treat community-acquired pneumonia? (2007) (25)
Safety of intravenous infusion of doripenem. (2009) (24)
Campylobacter fetus sepsis with mycotic aortic aneurysm. (1979) (24)
Value of noninvasive studies in community-acquired pneumonia. (1998) (24)
Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. (2007) (23)
Ticarcillin-clavulanate therapy for bacterial skin and soft tissue infections. (1991) (23)
New Diagnostic Tests for Pneumonia: What is Their Role in Clinical Practice? (2011) (23)
Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila. (2001) (23)
Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients. (1978) (23)
Performance measure of urinary antigen in patients with Streptococcus pneumoniae bacteremia. (2008) (23)
Impact of community-acquired methicillin-resistant Staphylococcus aureus in the hospital setting. (2007) (23)
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. (2016) (21)
Pneumonia in older adults: reversing the trend. (2005) (21)
A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens. (2017) (21)
Dermatobia hominis dermal myiasis. A furuncular lesion in a world traveler. (1985) (21)
Pneumonia and empyema caused by Clostridium sordellii. (1977) (21)
Treatment of Community-Acquired Pneumonia in Immunocompromised Adults (2020) (20)
Assessment of Time to Clinical Response, a Proxy for Discharge Readiness, among Hospitalized Patients with Community-Acquired Pneumonia Who Received either Ceftaroline Fosamil or Ceftriaxone in Two Phase III FOCUS Trials (2014) (20)
Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients (2015) (20)
A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia. (2003) (20)
Multicenter study of the clinical efficacy of imipenem/cilastatin for treatment of serious infections. (1985) (19)
Etiology and management of community-acquired pneumonia in Asia (2002) (19)
Identifying Barriers to Adult Pneumococcal Vaccination: An NFID Task Force Meeting (2012) (19)
Community-acquired pneumonia. What's needed for accurate diagnosis. (1996) (18)
Lack of Recurrence of Hyperlactatemia in HIV-Infected Patients Switched From Stavudine to Abacavir or Zidovudine (2004) (18)
An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic (2019) (18)
Diagnosis and Treatment of Clostridium difficile Infection (2016) (18)
Telithromycin new product overview. (2005) (18)
Reporting and publishing guidelines: article 12 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. (2012) (18)
Diffusibility of the newer cephalosporins into human interstitial fluids. (1984) (17)
Higher Pneumococcal Disease Vaccination Rates Needed to Protect More At-Risk US Adults (2009) (17)
The clinical relevance of penicillin-resistant Streptococcus pneumoniae: a new perspective. (2006) (17)
Antibiotics and adverse events: the role of antimicrobial stewardship programs in 'doing no harm'. (2019) (17)
Treatment of skin and soft-tissue infections. (1995) (17)
Evaluation and use of a rapid Staphylococcus aureus assay by an antimicrobial stewardship program. (2013) (16)
Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults (2021) (16)
Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe. (2017) (15)
The Evolving Role of Antimicrobial Stewardship in Management of Multidrug Resistant Infections. (2016) (15)
Judicious use of antibiotics to treat respiratory tract infections. (2002) (15)
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. (2018) (15)
A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic. (2009) (14)
Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study (2020) (14)
The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults. (2007) (14)
Necrotizing soft tissue infections (2003) (14)
Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study (2017) (14)
Performance measurement in community-acquired pneumonia: consequences intended and unintended. (2007) (14)
THE IMPORTANCE OF CHLAMYDIA PNEUMONIAE AS A PATHOGEN: THE 1996 CONSENSUS CONFERENCE ON CHLAMYDIA PNEUMONIAE INFECTIONS (1997) (14)
Clinical and Public Health Implications of Macrolide-Resistant Streptococcus pneumoniae (2002) (13)
Antipseudomonal penicillins. (1995) (13)
Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains. (2005) (13)
Determining the Duration of Therapy for Patients with Community-Acquired Pneumonia (2013) (12)
Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections. (1994) (12)
Duration and cessation of antimicrobial treatment. (2012) (12)
Real-Life Treatment of Acute Exacerbations of Chronic Bronchitis with Moxifloxacin or Macrolides (2006) (12)
Causes, Burden, and Prevention of Clostridium difficile Infection (2015) (12)
Infectious complications in diabetic patients. (1981) (11)
Timentin versus moxalactam in the treatment of skin and soft tissue infections. (1985) (11)
Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. (2018) (11)
Nosocomial (Health Care-Associated) Legionnaire's Disease. (2017) (11)
Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-Acquired Bacterial Pneumonia. (2020) (11)
Diagnosis and treatment of diabetic foot infections. (1999) (11)
Timentin versus piperacillin in the therapy of serious urinary tract infections. (1985) (11)
Community-acquired pneumonia. The changing picture. (1992) (11)
Repeat antimicrobial susceptibility testing of identical isolates (1989) (11)
Recurrent cellulitis after bypass surgery associated with psoriasis. (1984) (10)
Pharmacokinetics of intravenous cefmetazole with emphasis on comparison between predicted theoretical levels in tissue and actual skin window fluid levels (1989) (10)
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. (2016) (10)
Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities (2021) (10)
Group a streptococcus necrotizing fasciitis (2000) (9)
In vitro susceptibility of the Bacteroides fragilis group in community hospitals. (1986) (9)
Cefoperazone for the treatment of acute urinary tract infection: multicentered comparative and noncomparative studies. (1983) (9)
Cefoperazone versus cefamandole in the treatment of acute bacterial lower respiratory tract infections. (1983) (9)
Managing patients with recurrent acute exacerbations of chronic bronchitis: a common clinical problem (2004) (8)
Current Challenges in the Treatment of Community-Acquired Pneumonia (2004) (8)
Levels of antibiotic in human blood and interstitial fluid after oral administration of bacampicillin or phenoxymethyl penicillin and intravenous administration of amoxicillin or ampicillin. (1981) (8)
Charting the Path Forward Development, Goals and Initiatives of the 2019 IDSA Strategic Plan. (2019) (8)
A Phase 2 Study Comparing Two Doses of Radezolid to Linezolid in Adults with Uncomplicated Skin and Skin Structure Infections (uSSSI) (2008) (8)
Community-associated methicillin-resistant Staphylococcus aureas: not only a cause of skin infections, also a new cause of pneumonia. (2005) (8)
Methicillin-resistant Staphylococcus aureus (MRSA): focus on community-associated MRSA (2008) (8)
New Guidelines for Antimicrobial Prophylaxis in Surgery (2013) (8)
FLUOROQUINOLONES AND RESPIRATORY TRACT INFECTIONS: Do THEY WORK? (1997) (8)
What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia. (2008) (8)
Overview of Community-Acquired Respiratory Tract Infections (2003) (7)
Community-acquired respiratory infections : antimicrobial management (2003) (7)
Management of Community-Acquired Pneumonia (2003) (7)
Infections due to Corynebacterium group D2. Report of a case. (1990) (7)
2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study (2018) (7)
International Guidelines for the Treatment of Community-Acquired Pneumonia in Adults (2012) (7)
Empiric antimicrobial therapy of serious urinary tract infections. (1986) (7)
Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe. (2019) (7)
Urinary tract infections in obstetrics and gynecology. (1990) (7)
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point. (2017) (7)
Impact of the expansion of antimicrobial stewardship services during transitions of care at an academic hospital (2020) (7)
Therapy of skin, soft tissue, and bone infections with cefoxitin sodium. (1979) (7)
Levels of amdinocillin in human plasma and interstitial fluid following intravenous administration. (1983) (7)
Severe Acute Respiratory Syndrome (2012) (6)
Highlights From International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases (2011) (6)
Treatment of bacterial skin and soft tissue infections. (1991) (6)
Community-acquired pneumonia: new guidelines for management. (2001) (6)
Infectious complications in diabetic patients. (1994) (6)
Viral respiratory tract infections: increasing importance and a new pathogen. (2003) (6)
Clinical evaluation of ceftriaxone. (1984) (6)
Community-Acquired Pneumonia in Older Adults (2015) (6)
Team approach in the management of diabetic foot infections. (1987) (6)
Guideline tyranny: a response to the article by Baum and Kaltsas. (2008) (5)
Atypical pneumonia syndrome. (1981) (5)
New insights in the treatment by levofloxacin. (2004) (5)
Rapid detection of Streptococcus pneumoniae in community-acquired pneumonia (2006) (5)
A comparative study of bacampicillin hydrochloride, penicillin V, and amoxicillin in the treatment of acute tonsillitis and/or pharyngitis due to beta-hemolytic streptococci. (1981) (5)
Editorial Commentary: Optimizing Therapy for Community‐Acquired Pneumonia with the Goal of Rapid Resolution of Illness (2005) (5)
Keeping our Adult Patients Healthy and Active: The Role of Vaccines across the Lifespan (2010) (5)
Evaluation of cefoperazone in the therapy or urinary tract infections. (1982) (5)
Update of Legionella infections. (1999) (5)
Yield, clinical significance, and cost of a combination BACTEC plus Septi-Chek blood culture system (1987) (5)
Solutions to the Problem of Bacterial Resistance (2005) (5)
Clinical and Public Health Implications of Macrolide-Resistant Streptococcus pneumoniae. (2002) (5)
Canine model for the simultaneous measurement of antibiotic levels in tissues and bacterial killing rate (1986) (5)
Bullous skin lesions associated with Yersinia enterocolitica septicemia. (1984) (5)
ENTEROCOCCAL SENSITIVITY TO THIRD GENERATION CEPHALOSPORINS (1981) (5)
Highlights From Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children (2011) (4)
Treatment of Bacteriuria in Pregnancy (1992) (4)
Highlights of Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria (2019) (4)
Highlights From 2012 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Treatment of Diabetic Foot Infections (2013) (4)
Guiding in the Face of Minimal Evidence: A Strength, Not a Weakness, of Graded Clinical Practice Guidelines (2010) (4)
Optimal treatment strategies for community-acquired pneumonia: non-responders to conventional regimens. (2001) (4)
Shorter course therapy of serious respiratory infections: new data for new approaches to management. (2004) (4)
Prevention of bloodstream infections: basics and beyond. (2009) (4)
Case studies of lower respiratory tract infections: community-acquired pneumonia. (2010) (4)
Implementation of a Procalcitonin Assay Requires Appropriate Stewardship to Result in Improved Antimicrobial Use (2015) (3)
Pneumococcal Vaccination Remains a High Priority (2016) (3)
Rationale and Methods of the Study Protocol: Streptococcus pneumoniae Serotypes in Adults 18 Years and Older with Radiographically-Confirmed Community-Acquired Pneumonia (CAP) (2017) (3)
Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns. (2004) (3)
Duration and cessation of antimicrobial treatment. (2012) (3)
1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections (2018) (3)
Efficacy and Safety of Omadacycline in Chronic Kidney Disease (CKD) Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subgroup Analysis from the OASIS Tria (2017) (3)
Pooled Microbiological Findings and Efficacy Outcomes by Pathogen in Adults With Community-Acquired Bacterial Pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Trials of Lefamulin Versus Moxifloxacin (2021) (3)
The risk of prescribing antibiotics “just-in-case” there is infection (2017) (3)
Update on Preventing Pneumococcal Disease in Adults (2012) (3)
Effect of Rapid Molecular Diagnostic Testing and Antimicrobial Stewardship on Antimicrobial Therapy of Respiratory Infections (2017) (3)
Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment. (2020) (3)
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections. (2020) (3)
Meropenem-Vaborbactam vs. Piperacillin-Tazobactam in TANGO I (a Phase 3 Randomized, Double-blind Trial): Outcomes by Baseline MIC in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis (2017) (3)
Antibiotic Development Incentives That Reflect Societal Value of Antibiotics. (2020) (3)
Cefmenoxime versus cefoxitin in the treatment of serious bacterial infections. (1984) (3)
Duration of Antibiotic Therapy for Patients with Bacteremic Staphylococcus aureus Community-Acquired Pneumonia (2018) (3)
Lower respiratory tract infections. (2004) (2)
Another perspective: Reducing the overtreatment of pneumonia (2013) (2)
Optimizing therapy for community-acquired pneumonia with the goal of rapid resolution of illness. (2006) (2)
The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens. (2018) (2)
Management of staphylococcal and streptococcal infections. (1996) (2)
Leveraging Existing and Soon-to-Be-Available Novel Diagnostics for Optimizing Outpatient Antibiotic Stewardship in Patients with Respiratory Tract Infections. (2020) (2)
New Guidelines for the Management of Complicated Intra-Abdominal Infections (2010) (2)
Concurrent antibody rises to C psittaci and L pneumophila in a patient with psittacosis. (1982) (2)
Sepsis in Patients with Ventilator Associated Pneumonia due to Methicillin- Resistant Staphylococcus aureus: Incidence and Impact on Clinical outcomes (2017) (2)
Highlights From Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer: An Update by the Infectious Diseases Society of America (2011) (2)
Community-associated methicillin-resistant Staphylococcus aureas: not only a cause of skin infections, also a new cause of pneumonia (2005) (2)
Reply to Collins et al. and to Singh (2007) (2)
Pathways to Leadership: Reflections of Recent Infectious Diseases Society of America (IDSA) Leaders During Conception and Launch of the Inclusion, Diversity, Access, and Equity Movement Within the IDSA. (2020) (2)
Improving clinical practice guidelines--the answer is more clinical research. (2011) (2)
PATIENT RISK FACTORS IN COMMUNITY-ACQUIRED PNEUMONIA INFECTIONS OUTCOME FOLLOWING TREATMENT WITH GEMIFLOXACIN (2005) (2)
Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial (2019) (2)
Infectious Disease Clinics of North America. Community-acquired pneumonia: controversies and questions. Preface. (2013) (2)
1805. Impact of Antimicrobial Stewardship Interventions Using Rapid Molecular Testing on the Appropriate Use of Antiviral Therapy and Reduction of Unnecessary Antibiotic Therapy for Patients Admitted With Acute Influenza (2018) (2)
Highlights From the 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society on Management of Adults With Hospital-Acquired and Ventilator-Associated Pneumonia (2017) (2)
Consensus on early intervention in community-acquired pneumonia: Panel discussion (1996) (2)
New Community-Acquired Pneumonia Guideline: A Unified American Approach (2007) (2)
CARDIO-PULMONARY MEDICAL HISTORY AND THE EFFECT ON CLINICAL OUTCOME OF COMMUNITY-ACQUIRED PNEUMONIA INFECTIONS TREATED WITH GEMIFLOXACIN (2005) (2)
Studies on the use of antihistamines in cataract surgery. (1961) (2)
Pneumococcal vaccine: a different perspective. (1994) (2)
Acute bronchitis: an indication for antibiotic avoidance. (1999) (2)
Ventilator-associated pneumonia: gearing towards shorter-course therapy (2006) (2)
Reply to Tang and Lai. (2019) (2)
Patterns of Antibacterial Susceptibility Among Streptococcus pneumoniae Isolates Obtained from Patients With Community-acquired Pneumonia: Update from PROTEKT US Year 5 (2006) (2)
West Nile Virus: The First Pandemic of the Twenty-First Century (2002) (1)
The Role of Antibiotic Stewardship and Telemedicine in the Management of Multidrug-Resistant Infections. (2020) (1)
Is short course gemifloxacin therapy effective in at-risk community-acquired pneumonia (CAP) patients? (2006) (1)
New millennium: new antimicrobial agents for respiratory infections; but an old plea. (2000) (1)
Response of mice to transtracheal pulmonary inoculation of anaerobic bacteria (1982) (1)
664. Efficacy in Adults With Moderate to Severe Community-Acquired Bacterial Pneumonia (CABP) and Pneumonia Outcomes Research Team (PORT) Risk Class III to V: Results of a Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Outcomes (2019) (1)
Infectious complications in diabetic patients. (1981) (1)
Reply to Bush and Kaye. (2017) (1)
1374. Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic (2018) (1)
Antibiotic Development-D??j?? Vu: Are We Facing the "Preantibiotic Era" Again? (2007) (1)
Impact of FilmArray Technology for Rapid Identification of Bacteremias in a Community Teaching Hospital (2016) (1)
Management of community-acquired pneumonia: An appropriate-use tool (2001) (1)
International Respiratory Tract Infection Guidelines (2002) (1)
2237. Early Discontinuation of Antibacterials Is Safe for Patients with Community-Acquired Pneumonia (CAP) Who Have a Positive Viral Test, Negative Tests for Bacteria, and Low Procalcitonin (2019) (1)
Drug-Resistant Streptococcus pneumoniae for Community-Acquired Pneumonia: A Moving Target (2008) (1)
Legionella (2020) (1)
Unmet Needs for the Treatment of Moderate-to-Severe or Hospitalized Community-Acquired Pneumonia (2009) (1)
1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections (2018) (1)
A Phase II Randomized , Double-blind , Multicenter Study to Evaluate Ef fi cacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Con fi rmed to be Due to Gram-positive Pathogens (2017) (1)
New Guidelines for the Management of Intravascular Catheter-Related Infections (2010) (1)
663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials (2019) (1)
Reply to Yu et al. (2004) (1)
Using the Antibiotic Intensity Score to Evaluate Antibiotic Use in Hospitalized Patients With Community-Acquired Pneumonia With Known Versus Unknown Etiology: Results From the Community-Acquired Pneumonia Organization International Cohort Study (2016) (1)
The pattern of gram-negative-rod bacteremia in a community hospital. (1977) (0)
Early Steps Toward Ambulatory Antimicrobial Stewardship: Dental and Orthopedic Focus. (2019) (0)
Community-Acquired Pneumonia: New Data, New Guidelines (2006) (0)
Cryptococcal Laryngitis (2022) (0)
25 – Introduction to Respiratory Tract Infections (2012) (0)
O69 Modeling H. influenzae treatment response and progression in patients with COPD as they progress between acute exacerbation of chronic bronchitis (AECB) and community acquired pneumonia (CAP) (2009) (0)
Highlights From the Infectious Diseases Society of America Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults (2012) (0)
Impact of Guidelines on Antimicrobial Treatment of Respiratory Tract Infections (2007) (0)
Investigation of the risk factors for sporadically occurring Legionnaires` disease (1995) (0)
Antibiotic resistance: a local hospital or community problem. (1987) (0)
Improving Antimicrobial Stewardship in Patients With Cancer With the Use of Molecular Diagnostic Tests (2020) (0)
Primary care treatment in adults: outpatients (2011) (0)
THE EFFECT OF DISEASE SEVERITY ON CLINICAL OUTCOME WITH ACUTE EXACERBATION OF CHRONIC BRONCHITIS PATIENTS TREATED WITH GEMIFLOXACIN (2005) (0)
Changing the Culture of Ordering Urine Cultures (2020) (0)
Snapshots From 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC (Chicago, September 2011) (2012) (0)
Snapshots From 2012 International Conference on Emerging Infectious Diseases (Atlanta, March 2012) (2012) (0)
The Changing Use and Benefits of Anti–SARS-CoV-2 Monoclonal Antibodies (2022) (0)
Predisposing Factors and Antibiotic Use in Nosocomial Infections Caused by Xanthomonas maltophilia (1992) (0)
In Memoriam (1997) (0)
Is the risk of serious infections increased in patients with RA who receive treatment with antirheumatic drugs? (2008) (0)
A Tool for Appropriate Antibiotic Use in the Management of Community-Acquired Pneumonia (2001) (0)
Levofloxacin in the treatment of community acquired pneumonia. (1999) (0)
New Insights in the Treatment of Severe Infections in the Multiple-Drug Resistant Situation: Satellite Symposium to the 11th International Congress on Infectious Diseases, Cancun, March 2004: Proceedings (2004) (0)
1338. A Pooled Analysis of Patients With Wound Infections in the Phase 3 REVIVE Trials: Randomized, Double-blind Studies to EValuate the Safety and Efficacy of Iclaprim Vs. Vancomycin for trEatment of Acute Bacterial Skin and Skin Structure Infections (2018) (0)
Time to Clinical Stability in Patients with Ventilator-Associated Pneumonia due to Methicillin-Resistant Staphylococcus aureus Treated with Linezolid versus Vancomycin: Results from the IMPACT-HAP Study (2017) (0)
What Caused Cough and Hemoptysis in a Patient Recently Treated for Exudative Tonsillitis (2008) (0)
Safety and Efficacy of Gemifloxacin Compared to High Dose Amoxicillin/Clavulanate for the Treatment of Community-Acquired Pneumonia (CAP) of Suspected Pneumococcal Origin (2004) (0)
Should Amoxicillin Versus Amoxicillin-Clavulanate Be Used for Initial Empiric Antimicrobial Therapy of ABRS in Children ? (2012) (0)
2233. Efficacy and Symptom Resolution by Visit in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results (2019) (0)
Outcome And Differences Of MRSA Nosocomial Pneumonia: Early-Onset Versus Late-Onset (2011) (0)
Retrospective Assessment of Time to Being Dischargeable From Hospital for Community Acquired Pneumonia (CAP) Using Data From the FOCUS Trials (2013) (0)
Antimicrobial Stewardship—The Latest Trends and Opportunities (2014) (0)
Reduction of Clostridium difficile Infection in a Community Teaching Hospital Associated with Antimicrobial Stewardship Team Interventions on Fluoroquinolone Utilization (2017) (0)
Steroids for Community-Acquired Pneumonia (2015) (0)
Case Controlled Studies of the Transition State between AECB and CAP: Outpatient Antibiotic Failures, and Streptococcus pneumoniae (SP) Resistance in Hospitalized Patients with Underlying COPD (2007) (0)
The pneumococcal gauntlet has been thrown (2013) (0)
In memoriam James S. Tan, MD, MACP (2006) (0)
De-Escalation and Duration of Therapy - How Low Can We Go? (2014) (0)
Erratum: Update on preventing pneumococcal disease in adults (Infectious Diseases in Clinical Practice (2012) 20:1 (3-9)) (2013) (0)
Highlights From Clinical Practice Guidelines by the Infectious Diseases Society of America for the Diagnosis and Treatment of Seasonal Influenza (2019) (0)
Medication options for the treatment of CAP. (2006) (0)
Brief Note What You Need to Know About SARS (2003) (0)
Ambulatory management of lower respiratory tract infections. (1991) (0)
Diagnosis and treatment of staphylococcal diseases. (1989) (0)
CON: Is Combination Antibiotic Therapy Needed for Bacteremic Pneumococcal Pneumonia? (2008) (0)
Supplement on respiratory tract infections (2007) (0)
A comparison of six antistaphylococcal antibiotics. (1987) (0)
Clinical Infectious Disease: Atypical pneumonia (2008) (0)
443. Comparison of Clinical Characteristics of Endemic vs. SARS-CoV-2 Coronavirus Infection in Patients Admitted to a Community Teaching Hospital (2020) (0)
Safety and Tolerability of Gemifloxacin: A Review of Clinical Trial Data (2004) (0)
Urinary tract infections in the elderly. (1989) (0)
A 2012-2014 Global Antimicrobial Surveillance of Iclaprim Against Clinical Strains Causing Hospital-Associated Bacterial Pneumonia (HABP) and Skin and Skin Structure Infections (SSSI) (2016) (0)
Transitioning the Content of Infectious Diseases in Clinical Practice (2014) (0)
START Stewardship Tactics for Antimicrobial Resistance Trends (2015) (0)
The Benefit of Influenza Vaccines (2019) (0)
Erratum to: Treatment of Bacteriuria in Pregnancy (1993) (0)
RESISTANCE PHENOTYPES OF STREPTOCOCCUS PNEUMONIAE AND CLINICAL OUTCOME OF RESPIRATORY TRACT INFECTIONS TREATED WITH GEMIFLOXACIN (2005) (0)
Community-Acquired Pneumonia, Bacterial (2012) (0)
Clinical Outcomes For Patients With MRSA Ventilator-Associated Pneumonia Treated With Vancomycin Versus Linezolid: Results From The Impact-HAP Study (2011) (0)
Selected Reports From the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 2009, and the Annual Meeting of the Infectious Diseases Society of America, Philadelphia, October 2009 (2010) (0)
In Memoriam: Robert C. Moellering, Jr (2014) (0)
A Pharmacokinetically Enhanced Formulation of Amoxicillin/Clavulanate (PKE AMX/CA) 2000/125 mg for Drug-Resistant Streptococcus pneumoniae in Community-Acquired Pneumonia (CAP) (2005) (0)
Treatment of Pneumonia in Nonhospitalized Patients (2003) (0)
PIN4 COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE ANTIMICROBIAL TREATMENTS FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) (2005) (0)
Continuous Publishing (2022) (0)
Timentin Versus Piperacillin or Moxalactam in the Therapy of Acute Bacterial Infections (1984) (0)
Snapshots From 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC (Boston, September 11-15, 2010) (2011) (0)
[Clinical impact of appropriate use of antibiotic in hospital according to CARAT criteria]. (2008) (0)
Atypical pneumonia (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Thomas M. Jr. File?

Thomas M. Jr. File is affiliated with the following schools:

Ohio State University
Northeast Ohio Medical University